STOCK TITAN

Spero Therapeutics (SPRO) director awarded RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Spero Therapeutics director Patrick V.J.J. Vink received new equity awards. He was granted 10,000 restricted stock units, each representing one future common share upon vesting on June 23, 2027, subject to continued service. He was also awarded options on 20,000 shares at an exercise price of $2.15 per share, vesting in full on June 23, 2027 and expiring on June 23, 2036. Following these grants, he directly owns 85,000 common shares.

Positive

  • None.

Negative

  • None.
Insider VINK PATRICK V.J.J.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 20,000 $0.00 --
Grant/Award Common Stock 10,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct, null); Common Stock — 85,000 shares (Direct, null)
Footnotes (1)
  1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
RSU grant 10,000 RSUs Granted June 23, 2026; each RSU equals one common share at vesting
Option grant size 20,000 options Stock Option (right to buy) granted June 23, 2026
Option exercise price $2.15 per share Conversion/exercise price for 20,000 stock options
Option expiration June 23, 2036 Expiration date of the 20,000-share stock option grant
Equity holdings after grant 85,000 shares Total common shares directly owned after RSU grant
RSU vesting date June 23, 2027 RSUs vest in full on this date, subject to continued service
Option vesting date June 23, 2027 Options become fully exercisable on this date
restricted stock units ("RSUs") financial
"Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 2.1500 per share"
vesting financial
"The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: "2.1500" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
VINK PATRICK V.J.J.

(Last)(First)(Middle)
C/O SPERO THERAPEUTICS, INC.
675 MASSACHUSETTS AVENUE, 14TH FLOOR

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Spero Therapeutics, Inc. [ SPRO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026A10,000(1)A$0.0085,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.1506/23/2026A20,000 (2)06/23/2036Common Stock20,000$0.0020,000D
Explanation of Responses:
1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
2. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
/s/ Maegan Deare, Attorney-in-Fact for Patrick Vink06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Spero Therapeutics (SPRO) disclose for Patrick V.J.J. Vink?

Spero Therapeutics reported that director Patrick V.J.J. Vink received 10,000 restricted stock units and stock options for 20,000 shares on June 23, 2026. Both awards were granted at no cash cost as part of his equity compensation.

How many Spero Therapeutics shares does Patrick V.J.J. Vink hold after this Form 4?

After the reported awards, Patrick V.J.J. Vink directly owns 85,000 shares of Spero Therapeutics common stock. This total reflects his position following the 10,000 restricted stock units granted on June 23, 2026, which will settle in shares at vesting.

What are the key terms of Patrick V.J.J. Vink’s new stock options at Spero Therapeutics (SPRO)?

Vink received options covering 20,000 Spero Therapeutics shares at an exercise price of $2.15 per share. These options vest and become fully exercisable on June 23, 2027, contingent on his continued service as a director, and expire on June 23, 2036.

When do Patrick V.J.J. Vink’s Spero Therapeutics restricted stock units vest?

The 10,000 restricted stock units granted to Patrick V.J.J. Vink vest on June 23, 2027. Each RSU converts into one share of Spero Therapeutics common stock at that time, assuming he continues serving through the vesting date as specified.

Did Patrick V.J.J. Vink buy or sell Spero Therapeutics shares for cash in this Form 4?

The transactions reflect equity awards, not open-market buying or selling. Vink received 10,000 restricted stock units and 20,000 stock options as compensation grants, both reported with a transaction price of $0.00 per share, indicating no cash purchase or sale.